Phase II Trial of Selumetinib and Olaparib in RAS Pathway Mutant Ovarian and Endometrial Cancers
A phase II trial is comparing the efficacy of selumetinib plus olaparib versus selumetinib alone in patients with RAS pathway mutant recurrent or persistent ovarian and endometrial cancers.